Table 2. Association of pAMPK expression with clinicopathological features and pACC and pERK expression.
| Negative pAMPK | Positive pAMPK | P value | |
| n = 42 (%) | n = 76 (%) | ||
| Age, median (range) | |||
| <60 years | 23 (54.8) | 57 (75.0) | 0.024*C |
| ≥60 years | 19 (45.2) | 19 (25.0) | |
| Gender | |||
| Female | 3 (7.1) | 6 (7.9) | 1.000F |
| Male | 39 (92.9) | 70 (92.1) | |
| (Neo)Adjuvant | |||
| None | 20 (47.6) | 37 (48.7) | 0.912C |
| Any | 22 (52.4) | 39 (51.3) | |
| T | |||
| T1/T2 | 24 (57.1) | 59 (77.6) | 0.020*C |
| T3/T4 | 18 (42.9) | 17 (22.4) | |
| N | |||
| N0 | 31 (73.8) | 50 (65.8) | 0.369C |
| N1/N2 | 11 (26.2) | 26 (34.2) | |
| Stage | |||
| I/II | 21 (50.0) | 42 (55.3) | 0.583C |
| III/IV | 21 (50.0) | 34 (44.7) | |
| Site | |||
| Non-oral cavity | 8 (19.0) | 4 (5.3) | 0.026*F |
| Oral cavity | 34 (81.0) | 72 (94.7) | |
| Differentiation | |||
| Well to moderate | 34 (81.0) | 53 (69.7) | 0.200F |
| Poorly | 8 (19.0) | 23 (30.3) | |
| Margin | |||
| Negative | 27 (67.5) | 58 (77.3) | 0.253C |
| Positive | 13 (32.5) | 17 (22.7) | |
| Lymphovascular invasion | |||
| Negative | 25 (78.1) | 51 (83.6) | 0.577F |
| Positive | 7 (21.9) | 10 (16.4) | |
| pACC | |||
| Negative or low expression | 33 (78.6) | 62 (81.6) | 0.809F |
| High expression | 9 (21.4) | 14 (18.4) | |
| pErk | |||
| Negative | 33 (78.6) | 50 (65.8) | 0.206F |
| Positive | 9 (21.4) | 26 (34.2) |
C
χ2 test; FFisher’s exact test; *P<0.05.
T, tumor; N, node; pACC, phosphorylated acetyl-CoA carboxylase; pErK, phosphorylated extracellular signal-regulated kinase; pAMPK, phosphorylated AMP-activated protein kinase; n, patient number.